Achillion Pharmaceuticals Company Profile (NASDAQ:ACHN)

Analyst Ratings

Consensus Ratings for Achillion Pharmaceuticals (NASDAQ:ACHN) (?)
Ratings Breakdown: 1 Sell Rating(s), 2 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $9.71 (12.96% upside)

Analysts' Ratings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Show:
DateFirmActionRatingPrice TargetActions
7/14/2016Chardan CapitalInitiated CoverageSell$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/7/2016JMP SecuritiesUpgradeMarket Perform -> Outperform$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/12/2016Leerink SwannReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Robert W. BairdReiterated RatingOutperform$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Jefferies GroupReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Maxim GroupReiterated RatingBuy$11.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/8/2015William BlairReiterated RatingOutperform$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2015Cowen and CompanyReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2015Deutsche Bank AGReiterated RatingBuy$25.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2015Barclays PLCInitiated CoverageUnderweight$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/12/2014Wells Fargo & Co.Reiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/21/2014Credit Suisse Group AGReiterated RatingNeutral$4.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/15/2014FBR & CoInitiated CoverageOutperform$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2014Piper Jaffray Cos.UpgradeNeutral -> Overweight$5.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/3/2016Q116($0.14)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q4$0.09$0.12$31.40 million$31.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q3$0.09$0.19$32.62 million$33.82 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q2($0.18)($0.25)$0.71 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.22)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2015Q414($0.18)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q314($0.18)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.18)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014Q114($0.16)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2014Q413($0.16)($0.14)$0.01 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.20)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q113($0.15)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.17)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20163($0.16)($0.16)($0.16)
Q3 20161($0.19)($0.19)($0.19)
Q4 20163($0.23)($0.17)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Achillion Pharmaceuticals (NASDAQ:ACHN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/30/2015David ApelianinsiderSell10,000$10.50$105,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Mary Kay FentonCFOSell43,500$10.08$438,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Nicole VitulloDirectorSell550,000$10.17$5,593,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2015Nicole VitulloDirectorSell9,310$8.22$76,528.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2015Mary Kay FentonCFOSell13,125$16.00$210,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2015Milind DeshpandeCEOSell100,000$15.00$1,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014Ra Capital Management, LlcInsiderSell1,332,014$10.20$13,586,542.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014Ra Capital Management, LlcInsiderSell221,014$10.96$2,422,313.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2014Ra Capital Management, LlcMajor ShareholderSell2,372,915$11.17$26,505,460.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2014Ra Capital Management, LlcMajor ShareholderSell497,986$11.05$5,502,745.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014Ra Capital Management, LlcMajor ShareholderSell1,204,929$11.27$13,579,549.83View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2014Ra Capital Management, LlcMajor ShareholderSell2,595,071$11.29$29,298,351.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Ra Capital Management, LlcMajor ShareholderSell835,293$11.63$9,714,457.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Ra Capital Management, LlcMajor ShareholderSell2,711,352$11.33$30,719,618.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014Ra Capital Management, LlcMajor ShareholderSell2,112,867$11.35$23,981,040.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Joseph TruittEVPSell25,000$10.82$270,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Ra Capital Management, LlcMajor ShareholderSell331,396$10.96$3,632,100.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Milind DeshpandeCEOSell216,624$10.00$2,166,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Ra Capital Management, LlcMajor ShareholderSell4,235,000$9.53$40,359,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Michael D KishbauchDirectorSell495,812$9.40$4,660,632.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Gary E FrashierDirectorSell5,000$8.00$40,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2014Ra Capital Management, LlcInsiderSell880,000$8.40$7,392,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Gary E FrashierDirectorSell55,000$8.00$440,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Joseph TruittEVPSell25,000$7.82$195,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Qvt Associates Gp LlcMajor ShareholderSell1,819,551$7.70$14,010,542.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2014Qvt Associates Gp LlcMajor ShareholderSell128,649$7.66$985,451.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2014Joseph TruittEVPSell50,000$6.02$301,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2014Michael D KishbauchDirectorSell371,937$7.75$2,882,511.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2013Qvt Associates Gp Llcmajor shareholderSell170,239$3.34$568,598.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2013Qvt Associates Gp Llcmajor shareholderSell121,205$3.44$416,945.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2013Qvt Associates Gp Llcmajor shareholderSell289,141$3.24$936,816.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2013Qvt Associates Gp Llcmajor shareholderSell222,612$3.09$687,871.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2013Qvt Associates Gp Llcmajor shareholderSell92,803$3.11$288,617.33View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/22/2013Dennis LiottaDirectorBuy10,000$2.98$29,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013Ra Capital Management, LlcInsiderBuy1,110,000$2.55$2,830,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2013Jason FishermanDirectorBuy15,000$2.63$39,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2013Ra Capital Management, LlcInsiderBuy1,795,000$2.48$4,451,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/31/2013Ra Capital Management, LlcInsiderBuy1,186,007$2.45$2,905,717.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2013Ra Capital Management, LlcInsiderBuy2,369,229$2.79$6,610,148.91View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/11/2013Ra Capital Management, LlcInsiderBuy2,448,710$2.56$6,268,697.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2013Ra Capital Management, LlcInsiderBuy2,800,000$2.98$8,344,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Jason FishermanDirectorBuy5,000$6.83$34,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2013Dennis LiottaDirectorBuy5,000$6.47$32,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/9/2013Qvt Associates Gp Llcmajor shareholderBuy102,282$6.41$655,627.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/11/2013Qvt Associates Gp LlcMajor ShareholderBuy401,017$6.46$2,590,569.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2013Qvt Associates Gp LlcMajor ShareholderBuy390,944$6.33$2,474,675.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2013Qvt Associates Gp LlcMajor ShareholderBuy642,509$6.28$4,034,956.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/3/2013Qvt Associates Gp LlcMajor ShareholderBuy1,963,248$6.43$12,623,684.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Gary E FrashierDirectorSell5,000$8.17$40,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/21/2013Jason S FishermanDirectorBuy10,000$7.63$76,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2013Gary E FrashierDirectorSell5,000$8.37$41,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Jason S FishermanDirectorBuy10,000$7.87$78,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Achillion Pharmaceuticals (NASDAQ:ACHN)
DateHeadline
07/23/16 08:00 AMStocks Trend Analysis: Harsco Corporation (HSC) Hancock Holding Company (HBHC) Achillion Pharmaceuticals, Inc ... - iStreetWire
07/22/16 10:27 AM2 Biotech Stocks News And Price Trends: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Sarepta Therapeutics, Inc ... - The Voice Registrar
07/20/16 02:35 PMAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 02:35 PM2 Biotech Stocks News And Price Trends: PDL BioPharma (PDLI), Achillion Pharmaceuticals (NASDAQ:ACHN) - The Voice Registrar
07/20/16 07:10 AMAchillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : July 20, 2016 -
07/19/16 02:17 PMNews review of 2 biotech stocks: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Celgene Corporation (NASDAQ ... - The Voice Registrar
07/19/16 02:17 PMBiotech news that matter for investors: Novavax (NASDAQ:NVAX), Achillion Pharmaceuticals (NASDAQ:ACHN) - The Voice Registrar
07/18/16 02:16 PMEarnings Estimates to see: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - News Oracle
07/18/16 07:05 AMShare Performance Summary for: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Press Telegraph
07/17/16 07:03 AMNext Weeks Broker Price Targets For Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Fiscal Standard
07/17/16 07:03 AMAchillion Pharmaceuticals Inc. (ACHN) is Trading Lower on Unusual Volume for July 14 - Equities.com
07/15/16 12:53 PMAchillion Pharmaceuticals Inc Realized Volatility Hits Elevated Level - CML News
07/14/16 07:46 PMAchillion Pharma Initiated At Sell By Chardan, Sees ≥60% Downside
07/14/16 02:18 PMCrowd Rating and Earnings Recap for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Telanagana Press
07/14/16 11:08 AMStrong Sell Calls For Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) At 1 - Investor Newswire
07/14/16 04:20 AMCoverage initiated on Achillion Pharma by Chardan Capital Markets -
07/13/16 07:50 PMAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Earnings Rundown and Analyst Rating Recap - Telanagana Press
07/11/16 08:04 AMTrade of the Day: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - <p><a rel="nofollow" href="http://investorplace.com">InvestorPlace</a><a rel="nofollow" href="http://investorplace.com">InvestorPlace - Stock Market News, Stock Advice & Trading Tips</a></p> <p>Last week's rise above all of the major moving averages for Achillion Pharmaceuticals (NASDAQ:ACHN) was a powerful display of bullishness.</p> <p>The post <a rel="nofollow" href="http://investorplace.com/2016/07/trade-day-achillion-pharmaceuticals-nasdaq-achn/">Trade of the Day: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)</a> appeared first on <a rel="nofollow" href="http://investorplace.com">InvestorPlace</a>.</p>
07/11/16 07:03 AMCompany Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) Rally 13.82% - TheFounders Daily
07/11/16 07:03 AMStock Performance Rundown on: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Press Telegraph
07/10/16 02:16 PMAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN): Check on Company Stock Performance - Press Telegraph
07/10/16 02:16 PMCompany Share Performance in Review: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Press Telegraph
07/09/16 10:24 AMRa Capital Management LLC Increased Achillion Pharmaceuticals INC (NASDAQ:ACHN) by $5.67 Million as Shares ... - Press Telegraph
07/08/16 02:18 PMNews Sentiment and Impact Score Review for :Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Press Telegraph
07/08/16 07:13 AMAchillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : July 8, 2016 -
07/07/16 07:36 PMAchillion Pharmaceuticals, Inc. Stock Momentum Hits Strength - CML News
07/07/16 02:18 PMEarnings Review and Price Target Watch for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Press Telegraph
07/07/16 09:44 AMAchillion Pharmaceuticals (ACHN) Stock Up, JMP Upgrades -
07/07/16 07:10 AMAnalysts' Actions -- First Solar, Qualcomm, Red Hat, Zions and More -
07/06/16 02:17 PMWhich Way is Stock Sentiment Leaning on :Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Press Telegraph
07/06/16 07:04 AMBroker Outlook For Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Fiscal Standard
07/05/16 02:17 PMRecommendation View and Earnings Glance for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Press Telegraph
07/05/16 07:04 AMAchillion Pharmaceuticals Inc (NASDAQ:ACHN): Stock Sentiment - Engelwood Daily
07/04/16 07:03 AMShare Performance Recap for: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Press Telegraph
07/03/16 02:16 PMAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Impact Score and Stock Sentiment Recap - Press Telegraph
07/01/16 07:31 PMAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) News Sentiment Recap - Press Telegraph
06/27/16 07:03 AMAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Broker Price Targets For The Coming Week - Fiscal Standard
06/26/16 02:16 PMStock Performance Focus on: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Press Telegraph
06/22/16 07:21 AMCan These Upstarts Knock Gilead Sciences Off Its Perch? -
06/22/16 07:04 AMFirst Week of August 19th Options Trading For Achillion Pharmaceuticals (ACHN)
06/21/16 10:20 AMAchillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : June 21, 2016 -
06/21/16 07:04 AMWorth Watching Stock: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - iStreetWire
06/20/16 05:51 PMWhy Achillion Pharmaceuticals Is Down Big in 2016 - Progress on short-duration hepatitis C therapies has failed to ignite investors' interest.
06/20/16 02:17 PMAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Analyst Price Targets For The Coming Week - Fiscal Standard
06/20/16 07:25 AMAchillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : June 20, 2016 -
06/17/16 10:12 AMYesterday Stock's Price Swings: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) , Spark Therapeutics, Inc. (NASDAQ ... - Street Updates
06/16/16 02:18 PMAnalyst Recommended Stock: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - News Oracle
06/16/16 02:18 PMPrice Target Summary: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Smith & Wesson Holding Corporation ... - Beacon Chronicle
06/14/16 02:17 PMEarnings Expectations of the Stocks: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Tesoro Corporation (NYSE:TSO) - Beacon Chronicle
06/14/16 02:17 PMEarnings Expectations of the Stocks: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Tesoro Corporation (NYSE:TSO) - Beacon Chronicle

Social

About Achillion Pharmaceuticals

Achillion Pharmaceuticals logoAchillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body's immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ACHN
  • CUSIP: 00448Q20
Key Metrics:
  • Previous Close: $8.77
  • 50 Day Moving Average: $8.75
  • 200 Day Moving Average: $8.03
  • P/E Ratio: N/A
  • P/E Growth: -0.76
  • Market Cap: $1.18B
  • Beta: 2.27
  • Current Year EPS Consensus Estimate: $-0.64 EPS
  • Next Year EPS Consensus Estimate: $-0.22 EPS
Additional Links:
Achillion Pharmaceuticals (NASDAQ:ACHN) Chart for Monday, July, 25, 2016